Genentech, announced that the FDA approved Gazyva (obinutuzumab) plus bendamustine chemotherapy followed by Gazyva alone as a new treatment for...
Genentech, has announced that the FDA approved Gazyva (obinutuzumab), also known as GA 101, in combination with chlorambucil chemotherapy for...
Genentech, announced that the FDA approved a supplemental biologics license application (sBLA) for Gazyva (obinutuzumab) in combination with chlorambucil chemotherapy...
Genentech, a member of the Roche Group announced results from the Phase III GADOLIN study showing that Gazyva (obinutuzumab) plus...
Genentech, a member of the Roche Group announced that the FDA has accepted the company�s supplemental Biologics License Application (sBLA)...
Genentech/Roche announced results from the pivotal Phase III CLL14 study in previously untreated chronic lymphocytic leukemia (CLL) showing that Venclexta...
Roche announced data from the final analysis of the phase III CLL11 study evaluating Gazyva/Gazyvaro (obinutuzumab)-based treatment in previously untreated...
Genentech announced new, positive data from the second stage of the CLL 11 study. This Phase III study, conducted in...
Genentech/Roche announced updated data from a pivotal Phase III CLL14 study that highlights Venclexta (venetoclax) plus Gazyva (obinutuzumab) combination treatment...
Genentech, a member of the Roche Group has announced positive results from the Phase III GADOLIN study, which evaluated treatment...